Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Benitec Biopharma Ltd (NASDAQ: BNTC).

Full DD Report for BNTC

You must become a subscriber to view this report.


Recent News from (NASDAQ: BNTC)

Gene therapy players under pressure
The Nasdaq's selloff notwithstanding, most gene therapy stocks are in the red. This morning, Sangamo Therapeutics ( SGMO -21.1% ) reported data on SB-913 that disappointed investors. More news on: Sangamo Therapeutics, Inc., AVROBIO, MeiraGTx Holdings plc, Healthcare stocks news, Stocks ...
Source: SeekingAlpha
Date: September, 05 2018 10:58
FDA and NIH to loosen oversight of gene therapy development
Citing the need to safely expedite the development of gene therapies and the rapid scientific advances related to the gene editing, the FDA and NIH are backing trimmed down oversight of relevant clinical trials, specifically eliminating the duplication of oversight related to initial study...
Source: SeekingAlpha
Date: August, 16 2018 09:47
Benitec out-licenses rights to gene therapies to Axovant; shares up 26% premarket
Thinly traded nano cap Benitec Biopharma (NASDAQ: BNTC ) is up  26%  premarket on light volume in response to its license agreement with Axovant Sciences (NASDAQ: AXON ) for its Silence-and-Replace gene therapy for oculopharyngeal muscular dystrophy (OPMD), a  rare inherit...
Source: SeekingAlpha
Date: August, 09 2018 08:39
Axovant Sciences Failed To Mention Critical Information
On July 10th 2018 Axovant Sciences ( AXON ) announced a partnership with Benitec Biopharma ( BNTC ) for exclusive global rights to BB-301, now named AXO-AAV-OPMD, for the treatment of oculopharyngeal muscular dystrophy, or OPMD, and five additional gene therapy programs in neurological di...
Source: SeekingAlpha
Date: July, 15 2018 11:50
Has Benitec Biopharma Sold The Jewel In The Crown?
Has Benitec Biopharma ( BNTC ) sold the jewel in its crown? On Monday, Benitec Biopharma announced that it had signed a deal with Axovant Sciences ( AXON ) for the licensing of Benitec’s Oculopharyngeal Muscular Dystrophy (OPMD) preclinical asset, BB-301. The terms of the deal wil...
Source: SeekingAlpha
Date: July, 11 2018 11:36
Today's Research Reports on Stocks to Watch: Benitec Biopharma and Pfizer
NEW YORK, NY / ACCESSWIRE / July 10, 2018 / Shares of Pfizer may have ended up flat yesterday but it wasn't the greatest news day for the pharmaceutical giant. President Trump took to Twitter to raise his concerns on the company as well as other drug makers for recently increasing prices. S...
Source: ACCESSWIRE IA
Date: July, 10 2018 08:10
New Catalysts Could Send This $3 Medical Device Stock to $9
Cardiovascular remote monitoring solutions have been big successes for companies like iRhythym (IRTC) and Biotelemetry (BEAT); the latter has climbed from $2 to $48! New entrant Biotricity (BTCY) is jumping into the same market with a potentially superior product and under-appreciate...
Source: ACCESSWIRE IA
Date: July, 10 2018 07:30
Axovant Is Rebuilding Its Neuroscience Pipeline One Building Block At A Time
Recently, Axovant (AXON) reported that it would license a gene therapy from Benetic Biopharma (BNTC) for a rare genetic muscle disease. Axovant continues to add new products to its neuroscience pipeline to rebuild it and to regain shareholder trust. This is a good deal, and it was a ne...
Source: SeekingAlpha
Date: July, 09 2018 21:59
Midday Gainers / Losers (07/09/2018)
Gainers:  STAF +255% . BNTC +56% . EVK +26% . OTCPK:LFIN +17% . LEDS +15% . HELE +16% . NNDM +15% . TAT +14% . BBOX +12% . PVG +12% . More news on: Staffing 360 Solutions, Inc., Benitec, Ever-Glory International Group, Inc, Stocks on the move, , Rea...
Source: SeekingAlpha
Date: July, 09 2018 12:42
Premarket Gainers as of 9:05 am (07/09/2018)
BNTC +109%   inks gene therapy development deal with Axovant Sciences valued at up to $187.5M. More news on: Benitec, Staffing 360 Solutions, Inc., Black Box Corporation, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: July, 09 2018 09:14

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-141.861.881.881.86600
2018-12-131.97851.97851.97851.97852,009
2018-12-121.881.88941.88941.881,885
2018-12-111.831.871.8941.832,524
2018-12-101.821.82911.89991.77757,925

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-114501,21936.9155Short
2018-12-072,0813,68156.5336Short
2018-11-271002,3524.2517Cover
2018-11-261556,8032.2784Cover
2018-11-20250250100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BNTC.


About Benitec Biopharma Ltd (NASDAQ: BNTC)

Logo for Benitec Biopharma Ltd (NASDAQ: BNTC)

Not available

 

Contact Information

 

 

Current Management

  • Peter French / CEO, Managing Director
  • Greg West / Secretary

Current Share Structure

     


    Recent Filings from (NASDAQ: BNTC)

    Statement of beneficial ownership of common stock by certain persons
    Filing Type: SC 13GFiling Source: edgar
    Filing Date: May, 09 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 03 2018
    Prospectus filed under Rule 424(b)(5)
    Filing Type: 424B5Filing Source: edgar
    Filing Date: May, 01 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 01 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: April, 30 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: April, 24 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: February, 22 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: February, 22 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: January, 30 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: January, 23 2018

     

     


    Daily Technical Chart for (NASDAQ: BNTC)

    Daily Technical Chart for (NASDAQ: BNTC)


    Stay tuned for daily updates and more on (NASDAQ: BNTC)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: BNTC)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BNTC is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BNTC and does not buy, sell, or trade any shares of BNTC. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/